📊 COLL Key Takeaways
Investment Thesis
Collegium Pharmaceutical demonstrates strong fundamental health with robust revenue growth of 23.6% YoY, excellent profitability metrics including 59.3% gross margin and 23.0% operating margin, and exceptional free cash flow generation at 42% FCF margin. The company maintains a fortress balance sheet with minimal leverage (0.09x Debt/Equity) and strong liquidity ratios, supported by $231.3M in cash and $327.6M in annual free cash flow.
COLL Strengths
- Revenue growth of 23.6% YoY demonstrates strong market demand and execution
- Exceptional free cash flow margin of 42% indicates efficient operations and capital allocation
- Conservative leverage with 0.09x Debt/Equity ratio and strong interest coverage of 10.4x
- Solid liquidity position with 1.57x current ratio and $231.3M cash balance
- High gross margin of 59.3% reflects strong pricing power and product mix quality
- 8 Form 4 insider filings suggest active management engagement
COLL Risks
- Net income growth stalled at 0% YoY despite 23.6% revenue growth, suggesting margin pressure or one-time items
- Diluted EPS declined 7.0% YoY indicating share dilution or profitability challenges at bottom line
- Pharmaceutical sector subject to regulatory, patent expiration, and reimbursement risks
- ROA of 3.8% is modest for a pharmaceutical company, suggesting asset efficiency challenges
Key Metrics to Watch
- Net income and bottom-line margin trends to determine if current pressure reverses
- Operating cash flow sustainability and free cash flow generation consistency
- Revenue growth trajectory in context of product pipeline and market competition
- Debt levels and leverage ratios given acquisition or R&D investment activity
COLL Financial Metrics
💡 AI Analyst Insight
The 42.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
COLL Profitability Ratios
COLL vs Healthcare Sector
How COLLEGIUM PHARMACEUTICAL, INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
COLL Balance Sheet & Liquidity
COLL 5-Year Financial Trend
5-Year Trend Summary: COLLEGIUM PHARMACEUTICAL, INC's revenue has grown significantly by 152% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.29 reflects profitable operations.
COLL Growth Metrics (YoY)
COLL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $159.3M | $2.4M | $0.27 |
| Q2 2025 | $145.3M | $2.4M | $0.34 |
| Q1 2025 | $144.9M | $2.4M | $0.07 |
| Q3 2024 | $136.7M | $9.3M | $0.27 |
| Q2 2024 | $135.5M | -$4.4M | $-0.13 |
| Q1 2024 | $144.8M | -$17.4M | $-0.51 |
| Q3 2023 | $127.0M | $457.0K | $0.01 |
| Q2 2023 | $123.5M | -$4.4M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
COLL Capital Allocation
COLL SEC Filings
Access official SEC EDGAR filings for COLLEGIUM PHARMACEUTICAL, INC (CIK: 0001267565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COLL
What is the AI rating for COLL?
COLLEGIUM PHARMACEUTICAL, INC (COLL) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are COLL's key strengths?
Revenue growth of 23.6% YoY demonstrates strong market demand and execution. Exceptional free cash flow margin of 42% indicates efficient operations and capital allocation.
What are the risks of investing in COLL?
Net income growth stalled at 0% YoY despite 23.6% revenue growth, suggesting margin pressure or one-time items. Diluted EPS declined 7.0% YoY indicating share dilution or profitability challenges at bottom line.
What is COLL's revenue and growth?
COLLEGIUM PHARMACEUTICAL, INC reported revenue of $780.6M.
Does COLL pay dividends?
COLLEGIUM PHARMACEUTICAL, INC does not currently pay dividends.
Where can I find COLL SEC filings?
Official SEC filings for COLLEGIUM PHARMACEUTICAL, INC (CIK: 0001267565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COLL's EPS?
COLLEGIUM PHARMACEUTICAL, INC has a diluted EPS of $1.73.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.